Prescribing patterns of duloxetine in France: a prescription assessment study in real-world conditions
| Autor: | David Evans, Serge Perrot, Paul Valensi, Sireesha Pamulapati, Hafida Arkoub, Frédéric Rouillon, Beatrice Augendre-Ferrante, Hernan Picard |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Generalized anxiety disorder Adolescent Thiophenes Duloxetine Hydrochloride Off-label use chemistry.chemical_compound Internal medicine parasitic diseases medicine Duloxetine media_common.cataloged_instance Humans Pharmacology (medical) Medical prescription European union Psychiatry media_common Aged Pharmacology Aged 80 and over Depressive Disorder Major business.industry Contraindications Middle Aged medicine.disease Anxiety Disorders Antidepressive Agents Drug Utilization chemistry Major depressive disorder Antidepressant Female France business |
| Zdroj: | International journal of clinical pharmacology and therapeutics. 52(1) |
| ISSN: | 0946-1965 |
| Popis: | Duloxetine is a serotonin and norepinephrine reuptake inhibitor approved in the European Union for the treatment of major depressive disorder, generalized anxiety disorder, and diabetic peripheral neuropathic pain in adults. This study aimed to assess the real-world conditions of duloxetine use in France. Between April 2009 and January 2010, 290 dispensing pharmacies, randomly selected from a nationally representative list, included 1,104 patients who presented a duloxetine prescription and consented to the study. Demographic, clinical, and prescription data were extracted from pharmacy records and requested from prescribing physicians. Of the 294 patients with full data available, the mean age (standard deviation) was 54.5 (13.5) years; 74.1% were female; and 86.7% presented with a renewal prescription. 73.5% of patients had major depressive disorder; 3.4% generalized anxiety disorder; and 3.4% diabetic peripheral neuropathic pain. Overall, 78.2% (95% CI: 73.1; 82.8) of patients received duloxetine for an EU-approved indication; 95.2% (95% CI: 92.1; 97.4) of patients had no contra-indication to duloxetine; and 99.0% (95% CI: 97.0; 99.8) received an approved dose. Combining these three criteria, the overall approved use of duloxetine was 73.7% (95% CI: 68.3; 78.7). The strengths and limitations of the study design are discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|